Scientific Program

 

Day 1 –  Friday, September 27

09:00-09:15

Opening/Welcome Remarks

David Metreveli, President of GHA

Hasmik Gazinian, President of ARASL

Session 1                                                

Updated Epidemiology and Burden of Disease

Moderators: Robert Gish,  Hasmik Ghazinyan, Maia Butsashvili

 

 

 

09:15-09:30

Prevalence of Hepatitis B and associated risk factors in Georgia

Ana Kasradze (Georgia)

09:30-09:45

HBV in Georgia –  Challenges and opportunities

David Metreveli (Georgia)

09:45-10:00

HBV in Armenia

Mher Davidyants (Armenia)

10:00-10:15

HBV in Azerbaijan

Yusif Alkhazov (Azerbaijan)

 

10:15-10:30

Contradictions in the paradigm of diagnosis and treatment of chronic  HBV  infection in Uzbekistan

 

Erkin Musabaev (Uzbekistan)

10:30-10:50

HBV Worldwide

Fransisco Averhoff (CDC, USA)

10:50-11:10

Panel Discussion

 

 

 

 

11:10-11:30

Coffee Break

 

 

 

 

Session 2

Natural History, Immunology and Diagnostics of HBV Infection

Moderators:  George Lau, Elza Vashakidze, Mher Davidyants

 

 

 

11:30-11:50

Natural Course of HBV and predictors of disease progression

Robert Thimme (Germany)

11:50-12:00

Discussion

 

12:00-12:20

Viral replication and Immune response of HBV Infection

Robert Thimme (Germany)

12:20-12:30

Discussion

 

12:30-12:50

Current diagnostics and new markers of HBV infection 

Robert Gish (USA)

12:50-13:00

Discussion

 

 

 

 

13:00-14:00

Lunch

 

 

 

 

Session 3

Treatment of HBV

Moderators: Francesco Negro

David Metreveli,  Yusif Alkhazov

 

 

 

14:00-14:20

Treatment indication  – differences between USA, Europe and Asia

Geoffrey Dusheiko (UK)

14:20-14:30

Discussion

 

14:30-14:50

Choice of treatment and predictors of outcome

George Lau (China)

14:50-15:00

Discussion

 

15:00-15:20

Management of Normal ALT Subject

Shiv Sarin (India)

15:20-15:30

Discussion

 

15:30-15:50

Mechanisms of Viral Persistence: Maternal and Neonatal Factors

Shiv Sarin (India)

15:50-16:00

Discussion

 

16:00-16:20

When to stop NUC treatment?

George Lau (China)

16:20-16:30

Discussion

 

 

 

 

16:30-17:00

Coffee Break

 

 

 

 

Session 4

Case presentations and discussions

Panel:  Robert Gish,

Geoffrey Dusheiko,

George Lau

 

 

 

17:00-18:30

Case 1, Case 2, Case 3

Mamuka zakalashvili (Georgia)

Jaba Zarkua (Georgia)

Violeta Sargsyan (Armenia)

 

Day 2 –  Saturday, September 28

Session 5

Special Groups (Part 1)   

Moderators:  Robert Thimme,   Aregnaz Mkhitharyan, Vahktang Kerashvili   

 

 

 

09:00-09:20

HBV Co-infections – HDV, HCV, HIV

Geoffrey Dusheiko (UK)

09:20-09:30

Discussion

 

09:30-09:50

HBV related cirrhosis

Geoffrey Dusheiko (UK)

09:50-10:00

Discussion

 

10:00-10:20

HCC in HBV patients

Robert Gish (USA)

10:20-10:30

Discussion

 

10:30-10:50

Hepatitis D and HCC

Francesco Negro (Switzerland)

10:50-11:00

Discussion

 

 

 

 

11:00-11:30

Coffee Break

 

 

 

 

Session 6

Special Groups (Part 2)

Moderators:  Geoffrey Dusheiko,   Irakli Rtskhiladze, Violeta Sargsyan   

 

 

 

11:30-11:50

HBV reactivation under immunosuppression

Robert Gish (USA)

11:50-12:00

Discussion

 

12:00-12:20

HBV and chronic kidney disease

George Lau (China)

12:20-12:30

Discussion

 

12:30-12:50

HBV in Pregnant women  

Henry Chan (China)

12:50-13:00

Discussion

 

13:00-13:20

HBV – ACLF

Hasmik Ghazinyan (Armenia)

13:20-13:30

Discussion

 

13:30-13:50

New promising approaches in HBV treatment

Henry Chan (China)

13:50-14:00

Discussion

 

 

 

 

14:00-15:00

Lunch

 

 

 

 

Session 7

Case presentations and discussions

Panel:  Robert Gish,

Robert Thimme,

Henry Chan

 

 

 

15:00-16:30

Case 1, Case 2, Case 3

Jaba Zarkua (Georgia)

Mamuka zakalashvili (Georgia)

Violeta Sargsyan (Armenia)

 

 

 

16:30-16:50

Coffee Break

 

 

 

 

Session 8

HBV Elimination – Expectation or Reality?

Moderators:  Fransisco Averhoff, Amiran Gamkrelidze, Gayane Amaryan

 

 

 

16:50-17:10

HBV Elimination strategy

Antons Mozalevskis (Denmark)

17:10-17:30

Georgian experience in HCV elimination – is that a way towards HBV elimination?

 

Fransisco Averhoff (USA)

17:30-17:50

Are we ready to think about HBV elimination in Armenia?

Romela Abovyan (Armenia) 

17:50-18:10

Eliminating Hepatitis in Uzbekistan – Uzbekistan Hepatitis Elimination Pilot (UHEP)

 

Shakhlo Sadirova (Uzbekistan)

18:10-18:30

Panel Discussion

 

18:30-18:40

Summary and Closing Remarks

 

20:00 Gala Dinner

 

Close Menu